CARDIOGENESIS CORP/CA Form 8-K March 03, 2005

# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 8-K

#### Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 3, 2005

#### **CARDIOGENESIS CORPORATION**

(Exact name of registrant as specified in its charter)

California 000-28288 77-0223740

(State or other jurisdiction (Commission File Number) (IRS Employer of incorporation) Identification No.)

26632 Towne Centre Drive
Suite 320
Foothill Ranch, California 92610
(Address of principal executive offices, including zip code)

Registrant s telephone number, including area code: (714) 649-5000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Exhibit Index on Page 4

# **TABLE OF CONTENTS**

Item 2.02. Results of Operation and Financial Condition

Item 9.01. Exhibits

SIGNATURE

**EXHIBIT INDEX** 

**EXHIBIT 99.01** 

#### **Table of Contents**

#### **Item 2.02. Results of Operation and Financial Condition**

On March 3, 2005, the Company issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2004.

The press release is attached hereto as Exhibit 99.01 and is incorporated herein by this reference.

The information in this Form 8-K and the Exhibits attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

#### **Item 9.01. Exhibits**

Exhibit No. Description

99.01 Press Release of CardioGenesis Corporation, dated March 3, 2005 related to

financial results for the quarter and year ended December 31, 2004

2

#### **Table of Contents**

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARDIOGENESIS CORPORATION (Registrant)

Date: March 3, 2005 By: /s/ CHRISTINE G. OCAMPO

Christine G. Ocampo, Chief Financial Officer and

Secretary

3

#### **Table of Contents**

# **EXHIBIT INDEX**

Exhibit No. Description Sequential Page Number 99.01 Press Release of CardioGenesis Corporation, dated March 3, 2005, 5

relating to financial results for the quarter and year ended

December 31, 2004.

4